Open Payments

PAUL NUGENT

Type
Physician · Allopathic & Osteopathic Physicians / Family Medicine
Where
FT WRIGHT, KY
NPI
1932157435
Received
$158,104 in 20 records, 2019 to 2025 ($2,309 general, $155,795 research)
As principal investigator
$4,914,356 of research payments to others in 7,597 records
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2023General payment5$2,309
2022Research payment5$153,501
2020Research payment1$1,505
2019Research payment9$789

By company

CompanyRecordsAmountYears
Valneva Austria GmbH4$153,3732022
ModernaTX, Inc.5$2,3092023
Eli Lilly and Company2$1,6332020–2022
ABBVIE INC.9$7892019

By nature of payment

NatureRecordsAmount
Research payment15$155,795
Travel and Lodging4$1,898
Food and Beverage1$411

Records

DateCompanyAmountNatureFormProductStudyYear
2023-01-19ModernaTX, Inc.$1,227Travel and LodgingIn-kind items and services2023
2023-01-19ModernaTX, Inc.$411Food and BeverageIn-kind items and services2023
2023-01-19ModernaTX, Inc.$267Travel and LodgingIn-kind items and services2023
2023-01-19ModernaTX, Inc.$247Travel and LodgingIn-kind items and services2023
2023-01-19ModernaTX, Inc.$155Travel and LodgingIn-kind items and services2023
2022-08-15Valneva Austria GmbH$35,266Research paymentCash or cash equivalentA MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A L2022
2022-04-29Eli Lilly and Company$128Research paymentIn-kind items and servicesRANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN2022
2022-03-28Valneva Austria GmbH$36,742Research paymentCash or cash equivalentA MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A L2022
2022-03-14Valneva Austria GmbH$51,719Research paymentCash or cash equivalentA MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A L2022
2022-03-14Valneva Austria GmbH$29,644Research paymentCash or cash equivalentA MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A L2022
2020-06-29Eli Lilly and Company$1,505Research paymentIn-kind items and servicesRANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN2020
2019-07-10ABBVIE INC.$32Research paymentIn-kind items and servicesAndrogel Drug, EndocrinologyM16-1002019
2019-07-10ABBVIE INC.$23Research paymentIn-kind items and servicesAndrogel Drug, EndocrinologyM16-1002019
2019-04-05ABBVIE INC.$273Research paymentIn-kind items and servicesAndrogel Drug, EndocrinologyM16-1002019
2019-04-05ABBVIE INC.$58Research paymentIn-kind items and servicesAndrogel Drug, EndocrinologyM16-1002019
2019-04-05ABBVIE INC.$36Research paymentIn-kind items and servicesAndrogel Drug, EndocrinologyM16-1002019
2019-04-05ABBVIE INC.$18Research paymentIn-kind items and servicesAndrogel Drug, EndocrinologyM16-1002019
2019-04-05ABBVIE INC.$18Research paymentIn-kind items and servicesAndrogel Drug, EndocrinologyM16-1002019
2019-04-04ABBVIE INC.$204Research paymentIn-kind items and servicesAndrogel Drug, EndocrinologyM16-1002019
2019-04-04ABBVIE INC.$124Research paymentIn-kind items and servicesAndrogel Drug, EndocrinologyM16-1002019

Research payments naming this person as principal investigator

DateCompanyPaid toAmountStudyYear
2025-12-18SANOFI PASTEUR INC.Clinical Research Advantage Inc$1,226A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a C2025
2025-12-18SANOFI PASTEUR INC.Clinical Research Advantage Inc$1,284A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a C2025
2025-11-27SANOFI PASTEUR INC.Clinical Research Advantage Inc$1,896A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a C2025
2025-11-18SANOFI PASTEUR INC.Clinical Research Advantage Inc$3,443A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a C2025
2025-10-31SANOFI PASTEUR INC.Clinical Research Advantage Inc$1,206A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a C2025
2025-09-24PFIZER INC.SYNEXUS CLINICAL RESEARCH US INC$631A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED2025
2025-09-17PFIZER INC.SYNEXUS CLINICAL RESEARCH US INC$842A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED2025
2025-07-26PFIZER INC.SYNEXUS CLINICAL RESEARCH US INC$1,250A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED2025
2025-07-18PFIZER INC.SYNEXUS CLINICAL RESEARCH US INC$55,267A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED2025
2025-06-10SANOFI PASTEUR INC.Clinical Research Advantage Inc$20,433A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a C2025
2025-06-09SANOFI PASTEUR INC.Clinical Research Advantage Inc$10,500A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a C2025
2025-05-21SANOFI PASTEUR INC.Clinical Research Advantage Inc$29,963A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a C2025
2025-04-21SANOFI PASTEUR INC.Clinical Research Advantage Inc$50,386A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a C2025
2025-04-08VERTEX PHARMACEUTICALS INCORPORATEDSYNEXUS CLINICAL RESEARCH CINCINNATI$19,122A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Assoc2025
2025-03-14SANOFI PASTEUR INC.Clinical Research Advantage Inc$729A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a C2025
2025-03-12SANOFI PASTEUR INC.Clinical Research Advantage Inc$96,308A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a C2025
2025-03-07SANOFI PASTEUR INC.Clinical Research Advantage Inc$1,584A Parallel-group, Phase III, Multi-stage, Modified Double-blind, Multi-armed Study to Assess the Efficacy, Safety, and I2025
2025-02-24SANOFI PASTEUR INC.Clinical Research Advantage Inc$350,141A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a C2025
2025-01-13Novartis Pharmaceuticals CorporationSYNEXUS CLINICAL RESEARCH$18,862A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo2025
2025-01-01VERTEX PHARMACEUTICALS INCORPORATEDSYNEXUS CLINICAL RESEARCH CINCINNATI$104,872A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine2025
2024-12-31PFIZER INC.SYNEXUS CLINICAL RESEARCH US INC$421A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED2024
2024-12-10PFIZER INC.SYNEXUS CLINICAL RESEARCH US INC$8,605A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED2024
2024-11-26PFIZER INC.SYNEXUS CLINICAL RESEARCH US INC$9,564A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED2024
2024-11-08PFIZER INC.SYNEXUS CLINICAL RESEARCH US INC$8,289A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED2024
2024-11-01VERTEX PHARMACEUTICALS INCORPORATEDSYNEXUS CINCINNATI$22,126A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine2024
2024-10-21SANOFI PASTEUR INC.Clinical Research Advantage Inc$191A Parallel-group, Phase III, Multi-stage, Modified Double-blind, Multi-armed Study to Assess the Efficacy, Safety, and I2024
2024-10-05PFIZER INC.SYNEXUS CLINICAL RESEARCH US INC$6,099A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED2024
2024-09-11PFIZER INC.SYNEXUS CLINICAL RESEARCH US INC$31,864A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED2024
2024-08-28PFIZER INC.SYNEXUS CLINICAL RESEARCH US INC$7,748A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED2024
2024-08-06PFIZER INC.SYNEXUS CLINICAL RESEARCH US INC$31,638A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED2024
2024-06-05PFIZER INC.SYNEXUS CLINICAL RESEARCH US INC$12,725A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED2024
2024-05-29PFIZER INC.SYNEXUS CLINICAL RESEARCH US INC$42A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED2024
2024-05-24PFIZER INC.SYNEXUS CLINICAL RESEARCH US INC$74,540A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED2024
2024-05-01Novavax IncSYNEXUS CLINICAL RESEARCH US INC$250A 2-PART, PHASE 1/2, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A SARS-CoV-2 RECOMB2024
2024-04-25Novartis Pharmaceuticals CorporationSYNEXUS CLINICAL RESEARCH$27,510A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo2024
2024-04-24PFIZER INC.SYNEXUS CLINICAL RESEARCH US INC$42A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED2024
2024-04-15PFIZER INC.SYNEXUS CLINICAL RESEARCH US INC$293A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED2024
2024-04-05PFIZER INC.SYNEXUS CLINICAL RESEARCH US INC$17,620A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED2024
2024-03-28PFIZER INC.SYNEXUS CLINICAL RESEARCH US INC$26,430A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED2024
2024-03-27PFIZER INC.SYNEXUS CLINICAL RESEARCH US INC$8,151A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED2024
2024-03-08PFIZER INC.SYNEXUS CLINICAL RESEARCH US INC$33,555A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED2024
2024-02-27PFIZER INC.SYNEXUS CLINICAL RESEARCH US INC$84,834A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED2024
2024-02-24VERTEX PHARMACEUTICALS INCORPORATEDSYNEXUS CINCINNATI$443Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)2024
2024-02-14PFIZER INC.SYNEXUS CLINICAL RESEARCH US INC$2,433A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED2024
2024-02-13PFIZER INC.SYNEXUS CLINICAL RESEARCH US INC$9,481A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED2024
2024-02-07ABBVIE INC.SYNEXUS CLINICAL RESEARCH US INC$2,250A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( 2024
2024-02-07ABBVIE INC.SYNEXUS CLINICAL RESEARCH US INC$325A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( 2024
2024-02-01PFIZER INC.Synexus Clinical Research US Cincinnati$4,266A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED2024
2024-01-31SANOFI PASTEUR INC.Clinical Research Advantage Inc$1,500A Parallel-group, Phase III, Multi-stage, Modified Double-blind, Multi-armed Study to Assess the Efficacy, Safety, and I2024
2023-12-12PFIZER INC.Synexus Clinical Research US Inc Synexus Clinical Research US Inc$997A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED2023
2023-12-12PFIZER INC.Synexus Clinical Research US Inc Synexus Clinical Research US Inc$63A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED2023
2023-11-30PFIZER INC.Synexus Clinical Research US Cincinnati$403A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED2023
2023-11-16SANOFI PASTEUR INC.Clinical Research Advantage Inc$789A Parallel-group, Phase III, Multi-stage, Modified Double-blind, Multi-armed Study to Assess the Efficacy, Safety, and I2023
2023-11-10SANOFI PASTEUR INC.Clinical Research Advantage,inc$5,354A Parallel-group, Phase III, Multi-stage, Modified Double-blind, Multi-armed Study to Assess the Efficacy, Safety, and I2023
2023-11-08ABBVIE INC.SYNEXUS CLINICAL RESEARCH US INC$259A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe 2023
2023-10-19ABBVIE INC.SYNEXUS CLINICAL RESEARCH US INC$150A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe 2023
2023-10-18Rhythm Pharmaceuticals, Inc.Synexus Clinical Research US, Inc.$1,826RM-493-0222023
2023-10-17SANOFI PASTEUR INC.Clinical Research Advantage Inc$441A Parallel-group, Phase III, Multi-stage, Modified Double-blind, Multi-armed Study to Assess the Efficacy, Safety, and I2023
2023-10-12ABBVIE INC.SYNEXUS CLINICAL RESEARCH US INC$519A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe 2023
2023-10-06SANOFI PASTEUR INC.Clinical Research Advantage,inc$5,678A Parallel-group, Phase III, Multi-stage, Modified Double-blind, Multi-armed Study to Assess the Efficacy, Safety, and I2023
2023-09-15GlaxoSmithKline, LLC.SYNEXUS CLINICAL RESEARCH US INC$499A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTI-COUNT2023
2023-08-28SANOFI PASTEUR INC.Clinical Research Advantage Inc$6,264A Parallel-group, Phase III, Multi-stage, Modified Double-blind, Multi-armed Study to Assess the Efficacy, Safety, and I2023
2023-08-23GlaxoSmithKline, LLC.SYNEXUS CLINICAL RESEARCH US INC$499PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT2023
2023-07-20ABBVIE INC.SYNEXUS CLINICAL RESEARCH US INC$75A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe 2023
2023-07-11ABBVIE INC.SYNEXUS CLINICAL RESEARCH US INC$1,760A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe 2023
2023-06-28GlaxoSmithKline, LLC.SYNEXUS CLINICAL RESEARCH US INC$1,000A PHASE 3, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI COUNTRY STUDY TO2023
2023-06-28GlaxoSmithKline, LLC.SYNEXUS CLINICAL RESEARCH US INC$6,000A PHASE 3, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI COUNTRY STUDY TO2023
2023-06-28GlaxoSmithKline, LLC.SYNEXUS CLINICAL RESEARCH US INC$3,500A PHASE 3, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI COUNTRY STUDY TO2023
2023-06-27Novartis Pharmaceuticals CorporationSYNEXUS CLINICAL RESEARCH$6,709A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo2023
2023-06-21GlaxoSmithKline, LLC.SYNEXUS CLINICAL RESEARCH US INC$499A PHASE 3, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI COUNTRY STUDY TO2023
2023-06-20Janssen Research & Development, LLCOptimal Research, LLC$14,205A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants2023
2023-06-08ABBVIE INC.SYNEXUS CLINICAL RESEARCH US INC$3,594A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe 2023
2023-05-30ModernaTX, Inc.AES Cincinnati (DRS)$706A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno2023
2023-05-30ModernaTX, Inc.AES Cincinnati (DRS)$706A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno2023
2023-05-30ModernaTX, Inc.AES Cincinnati (DRS)$706A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno2023
2023-05-30ModernaTX, Inc.AES Cincinnati (DRS)$706A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno2023
2023-05-30ModernaTX, Inc.AES Cincinnati (DRS)$706A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno2023
2023-05-30ModernaTX, Inc.AES Cincinnati (DRS)$706A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno2023
2023-05-30ModernaTX, Inc.AES Cincinnati (DRS)$706A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno2023
2023-05-30ModernaTX, Inc.AES Cincinnati (DRS)$706A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno2023
2023-05-30ModernaTX, Inc.AES Cincinnati (DRS)$706A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno2023
2023-05-30ModernaTX, Inc.AES Cincinnati (DRS)$706A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno2023
2023-05-30ModernaTX, Inc.AES Cincinnati (DRS)$706A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno2023
2023-05-30ModernaTX, Inc.AES Cincinnati (DRS)$706A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno2023
2023-05-30ModernaTX, Inc.AES Cincinnati (DRS)$706A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno2023
2023-05-30ModernaTX, Inc.AES Cincinnati (DRS)$706A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno2023
2023-05-30ModernaTX, Inc.AES Cincinnati (DRS)$706A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno2023
2023-05-30ModernaTX, Inc.AES Cincinnati (DRS)$706A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno2023
2023-05-30ModernaTX, Inc.AES Cincinnati (DRS)$706A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno2023
2023-05-30ModernaTX, Inc.AES Cincinnati (DRS)$706A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno2023
2023-05-30ModernaTX, Inc.AES Cincinnati (DRS)$706A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno2023
2023-05-30ModernaTX, Inc.AES Cincinnati (DRS)$706A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno2023
2023-05-30ModernaTX, Inc.AES Cincinnati (DRS)$706A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno2023
2023-05-30ModernaTX, Inc.AES Cincinnati (DRS)$706A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno2023
2023-05-30ModernaTX, Inc.AES Cincinnati (DRS)$706A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno2023
2023-05-30ModernaTX, Inc.AES Cincinnati (DRS)$706A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno2023
2023-05-30ModernaTX, Inc.AES Cincinnati (DRS)$706A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno2023
2023-05-30ModernaTX, Inc.AES Cincinnati (DRS)$706A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno2023
2023-05-30ModernaTX, Inc.AES Cincinnati (DRS)$100A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno2023
2023-05-30ModernaTX, Inc.AES Cincinnati (DRS)$100A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno2023

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Kenton CountyFort Wright city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Fort Wright, KY, county Kenton County, KY, state Kentucky; placed by its city name.

MeasurePlace (city or town)
Fort Wright, KY
County
Kenton County, KY
State
Kentucky
Population B010035,887171,2884,534,824
Population, 2020 census P15,851169,0644,505,836
Median age B0100237.537.739.1
Under 18 B0100120.2%23.3%22.6%
65 and over B0100120.3%15.7%17.3%
Households B110012,31567,3671,814,469
Foreign born B050027.4%4.1%4.7%
Median household income B19013$105,024$80,548$63,726
Median family income B19113$128,036$103,206$81,505
Per capita income B19301$44,173$43,733$35,821
Poverty rate B170013.0%11.8%16.1%
Unemployment rate B230253.4%4.3%4.9%
Civilian labor force B230253,24792,9272,152,038
Mean commute (minutes) B0801319.522.324.0
Bachelor's degree or higher B1500345.3%37.4%27.6%
Housing units B250012,42573,2212,023,116
Owner-occupied B2500370.7%70.7%68.3%
Renters B2500329.3%29.3%31.7%
Median home value B25077$328,900$244,400$205,600
Median gross rent B25064$1,142$1,069$967
White, not Hispanic B0300284.5%85.2%81.5%
Black B030021.7%3.9%7.6%
Hispanic or Latino B030025.9%4.9%5.0%
Asian B030020.2%1.1%1.6%
American Indian and Alaska Native B030020.5%0.1%0.1%

Economy now FRED unemployment 4.7% in Sep 2026 (4.5% a year earlier); per capita personal income $60,835 in 2025, up 29% in five years (+3.9% after inflation); Unemployment rate: 5.1% in Sep 2016 to 4.7% in Sep 2026; low 4.0%, high 16.7% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Fort Wright, KY.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.